To treat hyperphosphataemia in adult patients receiving hemodialysis or peritoneal dialysis or for not dialysis adult patients.

THERAPEUTIC INDICATIONS

Sevelamer Carbonate Heaton 800 mg is indicated for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis.

Sevelamer Carbonate Heaton 800 mg is also indicated for the control of hyperphosphataemia in adult patients with chronic kidney disease not on dialysis with serum phosphorus ≥ 1.78 mmol/l.

Sevelamer Caarbonate Heaton 800 mg should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25-dihydroxy Vitamin D3 or one of its analogues to control the development of renal bone disease.

DISPENSING AND REIMBURSEMENT

Medicinal product is subjected to medical prescription. The medicinal product is covered by public health insurance.

 

Treatment of secondary hyperparathyroidism (HPT)

THERAPEUTIC INDICATIONS

Treatment of secondary hyperparathyroidism (HPT) in adult patients with end-stage renal disease (ESRD) on maintenance dialysis therapy.

Cinecalcet Heaton 30 mg or Cinacalcet heaton 60 mg may be used as part of a therapeutic regimen including phosphate binders and/or Vitamin D sterols.

 

 Reduction of hypercalcaemia in adult patients with:

• parathyroid carcinoma

• primary HPT for whom parathyroidectomy would be indicated on the basis of serum calcium levels (as defined by relevant treatment guidelines), but in whom parathyroidectomy is not clinically appropriate or is contraindicated

DISPENSING AND REIMBURSEMENT

Medicinal product is subjected to medical prescription. The medicinal product is covered by public health insurance.


Cinacalcet 30 mg

 

Cinacalcet 60 mg

 

Treatment of secondary hyperparathyroidism (HPT)

THERAPEUTIC INDICATIONS

Prevetion and treatment of secondary hyperparathyroidism (HPT) in adult patients with end-stage renal disease (ESRD) who are on haemodialysis. 

Rextol 5 mcg/ml
• Each 1 ml ampoule contains 5 micrograms of paricalcitol.
• Each 2 ml ampoule contains 10 micrograms of paricalcitol.

DISPENSING AND REIMBURSEMENT

Medicinal product is subjected to medical prescription. The medicinal product is covered by public health insurance.